Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
Molecular and Cellular Biochemistry|July 8, 2011
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical researchSilvio E Perea, Idania Baladron, Yanelda Garcia, et al.
Molecular and Cellular Biochemistry|June 26, 2008
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivoSilvio E Perea, Osvaldo Reyes, Idania Baladron, et al.
The Lancet. Respiratory Medicine|June 12, 2022
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialRolando Ochoa-Azze, Arturo Chang-Monteagudo, Yanet Climent-Ruiz, et al.
Vaccine|February 15, 2022
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicitySonia Pérez-Rodríguez, Meiby de la Caridad Rodríguez-González, Rolando Ochoa-Azze, et al.
Lancet Regional Health. Americas|September 20, 2021
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trialArturo Chang-Monteagudo, Rolando Ochoa-Azze, Yanet Climent-Ruiz, et al.
Med (New York, N.Y.)|August 23, 2022
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adultsMaría Eugenia Toledo-Romani, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, et al.
Lancet Regional Health. Americas|January 9, 2023
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trialMaría Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela-Silva, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 20, 2022
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in childrenRinaldo Puga-Gómez, Yariset Ricardo-Delgado, Chaumey Rojas-Iriarte, et al.
RSC Chemical Biology|April 1, 2022
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesiclesDarielys Santana-Mederos, Rocmira Perez-Nicado, Yanet Climent, et al.
Frontiers in Oncology|March 13, 2019
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With HeberprovacJesús A Junco, Ranfis Rodríguez, Franklin Fuentes, et al.
Pageof 12